VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2020 | Targeting low HER2 expression with antibody-drug conjugates

Giuseppe Curigliano • 19 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Lapatinib Trastuzumab Trastuzumab deruxtecan
Immuno-Oncology

Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, discusses low HER2 expression metastatic breast cancer and its treatment with antibody-drug conjugates. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Giuseppe Curigliano

2:52
Future research directions for breast cancer
Giuseppe Curigliano • 9 Dec 2021
3:10
Highlights from the St. Gallen Consensus Panel
Giuseppe Curigliano • 24 Mar 2021
6:54
Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer
Giuseppe Curigliano • 9 Dec 2021
2:42
Biomarker-driven therapies for triple-negative breast cancer
Giuseppe Curigliano • 26 Sep 2015

Related Videos

1:52
Highlights from ESMO Breast Cancer 2022
Benedetta Conte • 5 May 2022
1:55
Investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in HER2+ eBC
Benedetta Conte • 5 May 2022
1:26
The association of the HER2DX signatures with survival in TNBC
Benedetta Conte • 5 May 2022
0:46
Next generation sequencing in breast cancer
Maria Fernanda Mosele • 5 May 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals